MTA2 and mesothelioma: Analysis of MTA2 mutations in pan-cancer in the cBioPortal database revealed that MTA2 was amplified in cholangiocarcinoma, adrenocortical carcinoma, ovarian serous cystadenocarcinoma, liver hepatocellular, mesothelioma, pheochromocytoma, paraganglioma, and lung squamous cell carcinoma (Figure 3A).